{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:21:09Z","timestamp":1793996469135,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Burkitt\u2019s lymphoma (BL) is common in sub-Saharan Africa, yet diagnosis is often delayed due to limited pathology capacity. Here we evaluated blood-based liquid biopsies from 377 children and young adults with clinically suspected lymphoma at four hospitals in Tanzania and Uganda, assessing diagnostic accuracy and turnaround time (TAT). After extensive pathology capacity building, a gold-standard diagnosis was established using tissue morphology, a limited validated immunohistochemistry panel and independent dual histopathologist review. Using clinical features and circulating tumor DNA markers (\n                    <jats:italic>MYC<\/jats:italic>\n                    mutations,\n                    <jats:italic>MYC<\/jats:italic>\n                    \u2013immunoglobulin translocations and Epstein\u2013Barr virus fragmentomics), we trained six penalized logistic regression models with tenfold crossvalidation (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009212). The best-performing model was externally validated in a prospective real-world cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200956). Diagnostic accuracy, yield and TAT were compared head to head between liquid biopsy and the gold standard in 58 participants. The comprehensive model achieved the highest performance (area under the curve (AUC) 0.95, 95% confidence interval (95% CI) 0.901\u20130.981, sensitivity 0.86, specificity 0.95), confirmed by external validation (AUC 0.98, 95% CI 0.942\u20131.000). Liquid biopsy was the only diagnostic result available at the multidisciplinary review in 42% of participants and reduced median diagnostic TAT from 46.8\u2009d to 6.5\u2009d (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20094.42\u2009\u00d7\u200910\n                    <jats:sup>\u221210<\/jats:sup>\n                    ). These findings demonstrate that liquid biopsy enables fast, highly accurate molecular diagnosis of EBV\n                    <jats:sup>+<\/jats:sup>\n                    BL and may substantially reduce treatment delays in resource-limited settings.\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04291-z","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:03:15Z","timestamp":1773914595000},"page":"1754-1762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Liquid biopsy for the diagnosis of EBV-positive Burkitt\u2019s lymphoma in endemic areas"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5154-7872","authenticated-orcid":false,"given":"Clara","family":"Chamba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heavenlight","family":"Christopher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Josephat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Sseruyange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisen","family":"Ayitewala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-4940","authenticated-orcid":false,"given":"Kieran","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Dreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-9147","authenticated-orcid":false,"given":"Adam","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6118-542X","authenticated-orcid":false,"given":"Ismail","family":"Legason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Otim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscus","family":"Mapendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Mnango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Advera","family":"Ngaiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7226-0168","authenticated-orcid":false,"given":"Alex","family":"Mremi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edrick","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Achola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-7551","authenticated-orcid":false,"given":"William","family":"Mawalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehema","family":"Shungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Mkwizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Chirande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6501-535X","authenticated-orcid":false,"given":"Hadija","family":"Mwamtemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salama","family":"Mahawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-0991","authenticated-orcid":false,"given":"Godlove","family":"Sandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heronima J.","family":"Kashaigili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0131la","family":"Gerlevik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Shadrack","family":"Ntemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Magorosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mbwambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malale","family":"Tungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ogwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraja","family":"Chiwanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8273-9831","authenticated-orcid":false,"given":"Sam M.","family":"Mbulaiteye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"El Mouden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Balandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-1795","authenticated-orcid":false,"given":"Liz","family":"Morrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-1507","authenticated-orcid":false,"given":"Dimitrios","family":"Vavoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3938-8490","authenticated-orcid":false,"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"4291_CR1","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","volume":"382","author":"V Minard-Colin","year":"2020","unstructured":"Minard-Colin, V. et al. Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children. N. Engl. J. Med. 382, 2207\u20132219 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4291_CR2","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/bloodadvances.2024015234","volume":"9","author":"WF Mawalla","year":"2025","unstructured":"Mawalla, W. F. et al. Rituximab for children with EBV-positive Burkitt lymphoma in East Africa. Blood Adv. 9, 2393\u20132401 (2025).","journal-title":"Blood Adv"},{"key":"4291_CR3","doi-asserted-by":"crossref","unstructured":"Solares, S., Le\u00f3n, J. & Garc\u00eda-Guti\u00e9rrez, L. The functional interaction between Epstein\u2013Barr virus and MYC in the pathogenesis of Burkitt lymphoma. Cancers 16, 4212 (2024).","DOI":"10.3390\/cancers16244212"},{"key":"4291_CR4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","volume":"133","author":"BM Grande","year":"2019","unstructured":"Grande, B. M. et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood 133, 1313\u20131324 (2019).","journal-title":"Blood"},{"key":"4291_CR5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/0277-5379(93)90009-T","volume":"19","author":"A Geser","year":"1983","unstructured":"Geser, A. et al. Epstein-Barr virus markers in a series of Burkitt\u2019s lymphomas from the West Nile District, Uganda. Eur. J. Cancer Clin. Oncol. 19, 1393\u20131404 (1983).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"4291_CR6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"4291_CR7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","volume":"8","author":"C L\u00f3pez","year":"2022","unstructured":"L\u00f3pez, C. et al. Burkitt lymphoma. Nat. Rev. Dis. Primers 8, 78 (2022).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"4291_CR8","doi-asserted-by":"crossref","first-page":"e0299777","DOI":"10.1371\/journal.pone.0299777","volume":"19","author":"PB Hesseling","year":"2024","unstructured":"Hesseling, P. B. et al. Burkitt lymphoma: the effect of age, sex and delay to diagnosis on treatment completion and outcome of treatment in 934 patients in Cameroon. PLoS ONE 19, e0299777 (2024).","journal-title":"PLoS ONE"},{"key":"4291_CR9","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1182\/bloodadvances.2022009398","volume":"7","author":"WF Mawalla","year":"2023","unstructured":"Mawalla, W. F. et al. Treatment delays in children and young adults with lymphoma: report from an East Africa lymphoma cohort study. Blood Adv. 7, 4962\u20134965 (2023).","journal-title":"Blood Adv."},{"key":"4291_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-9378-8-36","volume":"8","author":"GC Buckle","year":"2013","unstructured":"Buckle, G. C. et al. Factors influencing time to diagnosis and initiation of treatment of endemic Burkitt lymphoma among children in Uganda and western Kenya: a cross-sectional survey. Infect. Agent Cancer 8, 1\u201316 (2013).","journal-title":"Infect. Agent Cancer"},{"key":"4291_CR11","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5586-4","volume":"19","author":"K Antel","year":"2019","unstructured":"Antel, K. et al. The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting. BMC Cancer 19, 384 (2019).","journal-title":"BMC Cancer"},{"key":"4291_CR12","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2141.2011.08772.x","volume":"154","author":"KN Naresh","year":"2011","unstructured":"Naresh, K. N. et al. Lymphomas in sub-Saharan Africa\u2014what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research?. Br. J. Haematol. 154, 696\u2013703 (2011).","journal-title":"Br. J. Haematol."},{"key":"4291_CR13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71\u201388 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"4291_CR14","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz, D. M. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat. Biotechnol. 39, 1537\u20131547 (2021).","journal-title":"Nat. Biotechnol."},{"key":"4291_CR15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55428-y","volume":"16","author":"DV Vavoulis","year":"2025","unstructured":"Vavoulis, D. V. et al. Multimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals. Nat. Commun. 16, 430 (2025).","journal-title":"Nat. Commun."},{"key":"4291_CR16","volume":"23","author":"HQ Si","year":"2024","unstructured":"Si, H. Q. et al. Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications. Mol. Cancer 23, 265 (2024).","journal-title":"Mol. Cancer"},{"key":"4291_CR17","doi-asserted-by":"crossref","DOI":"10.1017\/pcm.2023.1","volume":"1","author":"C Chamba","year":"2023","unstructured":"Chamba, C., Mbulaiteye, S. M., Balandya, E. & Schuh, A. Clinical application of circulating cell-free lymphoma DNA for fast and precise diagnosis of Burkitt lymphoma: precision medicine for sub-Saharan Africa. Camb. Prism Precis. Med. 1, e13 (2023).","journal-title":"Camb. Prism Precis. Med."},{"key":"4291_CR18","doi-asserted-by":"crossref","unstructured":"Editorial. Turning the tide of early cancer detection. Nat. Med. 30, 1217 (2004).","DOI":"10.1038\/s41591-024-03046-y"},{"key":"4291_CR19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","volume":"1","author":"DW Cescon","year":"2020","unstructured":"Cescon, D. W., Bratman, S. V., Chan, S. M. & Siu, L. L. Circulating tumor DNA and liquid biopsy in oncology. Nat. Cancer 1, 276\u2013290 (2020).","journal-title":"Nat. Cancer"},{"key":"4291_CR20","doi-asserted-by":"crossref","first-page":"e2400210","DOI":"10.1200\/GO.24.00210","volume":"11","author":"C Chamba","year":"2025","unstructured":"Chamba, C. et al. Targeted next-generation sequencing of cell-free DNA to detect MYC-immunoglobulin translocation and Epstein-Barr virus DNA in plasma of Burkitt lymphoma patients in East Africa. JCO Glob. Oncol. 11, e2400210 (2025).","journal-title":"JCO Glob. Oncol."},{"key":"4291_CR21","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","volume":"44","author":"J Richter","year":"2012","unstructured":"Richter, J. et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 44, 1316\u20131320 (2012).","journal-title":"Nat. Genet."},{"key":"4291_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31355-8","volume":"13","author":"B Burkhardt","year":"2022","unstructured":"Burkhardt, B. et al. Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nat. Commun. 13, 3881 (2022).","journal-title":"Nat. Commun."},{"key":"4291_CR23","first-page":"3031","volume":"109","author":"G Martire","year":"2024","unstructured":"Martire, G. et al. TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification. Haematologica 109, 3031\u20133036 (2024).","journal-title":"Haematologica"},{"key":"4291_CR24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41375-021-01444-6","volume":"36","author":"AM Newman","year":"2022","unstructured":"Newman, A. M. et al. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. Leukemia 36, 781\u2013789 (2022).","journal-title":"Leukemia"},{"key":"4291_CR25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","volume":"44","author":"C Love","year":"2012","unstructured":"Love, C. et al. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 44, 1321\u20131325 (2012).","journal-title":"Nat. Genet."},{"key":"4291_CR26","first-page":"E5115","volume":"115","author":"WKJ Lam","year":"2018","unstructured":"Lam, W. K. J. et al. Sequencing-based counting and size profiling of plasma Epstein\u2013Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc. Natl Acad. Sci. USA 115, E5115\u2013E5124 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4291_CR27","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.surg.2015.12.029","volume":"159","author":"JV Carter","year":"2016","unstructured":"Carter, J. V., Pan, J., Rai, S. N. & Galandiuk, S. ROC-ing along: evaluation and interpretation of receiver operating characteristic curves. Surgery 159, 1638\u20131645 (2016).","journal-title":"Surgery"},{"key":"4291_CR28","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/diagnostics13071288","volume":"13","author":"IM Diaz","year":"2023","unstructured":"Diaz, I. M. et al. Pre-analytical evaluation of Streck cell-free DNA blood collection tubes for liquid profiling in oncology. Diagnostics 13, 1288 (2023).","journal-title":"Diagnostics"},{"key":"4291_CR29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma, L. et al. Liquid biopsy in cancer: current status, challenges and future prospects. Signal. Transduct. Target Ther. 9, 336 (2024).","journal-title":"Signal. Transduct. Target Ther."},{"key":"4291_CR30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa2304714","volume":"390","author":"DC Chung","year":"2024","unstructured":"Chung, D. C. et al. A cell-free DNA blood-based test for colorectal cancer screening. N. Engl. J. Med. 390, 973\u2013983 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4291_CR31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-025-00795-x","volume":"25","author":"DC Bruhm","year":"2025","unstructured":"Bruhm, D. C. et al. Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection. Nat. Rev. Cancer 25, 341\u2013358 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"4291_CR32","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMra2025746","volume":"387","author":"M Roschewski","year":"2022","unstructured":"Roschewski, M., Staudt, L. M. & Wilson, W. H. Burkitt\u2019s lymphoma. N. Engl. J. Med. 387, 1111\u20131122 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4291_CR33","volume":"4","author":"NK El-Mallawany","year":"2017","unstructured":"El-Mallawany, N. K. et al. Beyond endemic Burkitt lymphoma: navigating challenges of differentiating childhood lymphoma diagnoses amid limitations in pathology resources in Lilongwe, Malawi. Glob. Pediatr. Health 4, 2333794X17715831 (2017).","journal-title":"Glob. Pediatr. Health"},{"key":"4291_CR34","volume":"11","author":"RR Xian","year":"2021","unstructured":"Xian, R. R. et al. Plasma EBV DNA: a promising diagnostic marker for endemic Burkitt lymphoma. Front. Oncol. 11, 804083 (2021).","journal-title":"Front. Oncol"},{"key":"4291_CR35","volume":"1","author":"K Volesky-Avellaneda","year":"2025","unstructured":"Volesky-Avellaneda, K. et al. Circulating plasma EBV DNA: a potential tool to facilitate diagnosis of pediatric Burkitt lymphoma in sub-Saharan Africa. Blood Glob. Hematol. 1, 100025 (2025).","journal-title":"Blood Glob. Hematol."},{"key":"4291_CR36","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.3390\/cancers16142505","volume":"16","author":"C Nicholas","year":"2024","unstructured":"Nicholas, C. et al. Point of care liquid biopsy for cancer treatment-early experience from a community center. Cancers 16, 2505 (2024).","journal-title":"Cancers"},{"key":"4291_CR37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2022.11.007","volume":"24","author":"LE Raez","year":"2023","unstructured":"Raez, L. E. et al. Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC). Clin. Lung Cancer 24, 120\u2013129 (2023).","journal-title":"Clin. Lung Cancer"},{"key":"4291_CR38","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","volume":"379","author":"RB Corcoran","year":"2018","unstructured":"Corcoran, R. B. & Chabner, B. A. Application of cell-free DNA analysis to cancer treatment. N. Engl. J. Med. 379, 1754\u20131765 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4291_CR39","volume":"48","author":"L Morrell","year":"2025","unstructured":"Morrell, L. et al. Diagnosing Burkitt lymphoma in sub-Saharan Africa by sequencing of circulating tumor DNA: a comparative microcosting study. Value Health Reg. Issues 48, 101113 (2025).","journal-title":"Value Health Reg. Issues"},{"key":"4291_CR40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s44250-024-00171-w","volume":"3","author":"GM Ruhago","year":"2024","unstructured":"Ruhago, G. M., Tungu, M., Morrell, L. & The AL-REAL Consortium. Understanding micro costing a genomics-based diagnostic in a resource-limited setting: experiences and challenges from a Burkitt lymphoma study in sub-Saharan Africa. Discover Health Systems 3, 106 (2024).","journal-title":"Discover Health Systems"},{"key":"4291_CR41","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/13696998.2022.2082777","volume":"25","author":"F Inturrisi","year":"2022","unstructured":"Inturrisi, F. & Berkhof, J. Pricing of HPV tests in Italian tender-based settings. J. Med. Econ. 25, 762\u2013768 (2022).","journal-title":"J. Med. Econ."},{"key":"4291_CR42","doi-asserted-by":"crossref","first-page":"e0154893","DOI":"10.1371\/journal.pone.0154893","volume":"11","author":"J Stover","year":"2016","unstructured":"Stover, J. et al. What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the fast-track approach. PLoS ONE 11, e0154893 (2016).","journal-title":"PLoS ONE"},{"key":"4291_CR43","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09553-w","volume":"22","author":"ID Legason","year":"2022","unstructured":"Legason, I. D. et al. A protocol to clinically evaluate liquid biopsies as a tool to speed up diagnosis of children and young adults with aggressive infection-related lymphoma in East Africa \u2018(AI-REAL)\u2019. BMC Cancer 22, 484 (2022).","journal-title":"BMC Cancer"},{"key":"4291_CR44","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2141.2011.08771.x","volume":"154","author":"KN Naresh","year":"2011","unstructured":"Naresh, K. N. et al. Diagnosis of Burkitt lymphoma using an algorithmic approach\u2014applicable in both resource-poor and resource-rich countries. Br. J. Haematol. 154, 770\u2013776 (2011).","journal-title":"Br. J. Haematol."},{"key":"4291_CR45","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.jpi.2023.100188","volume":"14","author":"A Mremi","year":"2023","unstructured":"Mremi, A. et al. Diagnostic validation of a portable whole slide imaging scanner for lymphoma diagnosis in resource-constrained setting: a cross-sectional study. J. Pathol. Inform. 14, 100188 (2023).","journal-title":"J. Pathol. Inform."},{"key":"4291_CR46","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568\u2013576 (2012)","journal-title":"Genome Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04291-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04291-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04291-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:03:42Z","timestamp":1779285822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04291-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4291"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04291-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6820773\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}